C3 Jian Presents at Jefferies 2015 Microbiome Summit

LOS ANGELES, California — December 16, 2015 — C3 Jian, Inc., a private biotechnology company focused on the development and commercialization of novel therapeutics aimed at reengineering the human microbiome, announced their participation in the Jefferies 2015 Microbiome Summit held in Boston, MA. Brian Varnum, C3 Jian’s Chief Development Officer, presented an overview of the Company’s microbiome programs.

The Company’s lead program, C16G2, is the first peptide therapeutic derived from the proprietary platform technology referred to as STAMPs (Specifically Targeted Antimicrobial Peptides).  STAMP technology specifically targets pathogenic bacteria, to correct dysbiosis of microbiome communities.  The result is a microbiome reengineered to restore a healthy ecology with the potential for a lasting therapeutic benefit.  C16G2 targets the specific elimination of Streptococcus mutans, the main acid-producing bacterium associated with dental caries.

C3 Jian reported evidence that preliminary metagenomics data from the first Phase 2 human clinical study confirms the selective activity of C16G2 in reengineering the oral microbiome.

The target indication for C16G2 is the prevention of dental caries in adults, adolescents and pediatrics.  According to the Centers for Disease Control and Prevention, dental caries, also known as tooth decay or cavities, is the most common chronic childhood disease.  In the U.S. alone, over $100 billion is spent annually on oral health expenditures covered by insurance.  The majority of these expenses are directly related to dental caries.

C3 Jian’s other microbiome program is being developed for Clostridium difficile infection using an orally-administered formulation to deliver a STAMP to the regions of the lower GI tract.  The company is planning to file an IND in the first half of 2017.

 

About C3 Jian, Inc.
C3 Jian is a clinical-stage biotechnology company focused on improving human health through the development and commercialization of targeted, pathogen-specific, antimicrobials (STAMPs) that treat and prevent diseases caused by microbial dysbiosis.  The proprietary STAMP platform technology has potential applications to a variety of bacterial infections, and disorders, particularly related to the human microbiome.  C3 Jian is based in Los Angeles, California. For more information, please visit www.c3-jian.com.

Media Contact: Todd Patrick (T) 310.665.2928 x242, (Email) tpatrick@c3-jian.com or Pierre Kyme (T) 310.665.2928 x234, (Email) pkyme@c3-jian.com.

Leave a Reply